Cargando…

Real-World Experiences With Facilitated Subcutaneous Immunoglobulin Substitution in Patients With Hypogammaglobulinemia, Using a Three-Step Ramp-Up Schedule

Immunoglobulin replacement therapy with facilitated subcutaneous immunoglobulin (fSCIg) can be self-administrated at home and given at longer intervals compared to subcutaneous immunoglobulin (SCIg) therapy, but real-word experience of home-based fSCIg therapy is limited. Herein we present our real-...

Descripción completa

Detalles Bibliográficos
Autores principales: Hustad, Nina B., Degerud, Hanna M., Hjelmerud, Ingrid, Fraz, Mai S. A., Nordøy, Ingvild, Trøseid, Marius, Fevang, Børre, Aukrust, Pål, Jørgensen, Silje F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8127781/
https://www.ncbi.nlm.nih.gov/pubmed/34012453
http://dx.doi.org/10.3389/fimmu.2021.670547
_version_ 1783694013431283712
author Hustad, Nina B.
Degerud, Hanna M.
Hjelmerud, Ingrid
Fraz, Mai S. A.
Nordøy, Ingvild
Trøseid, Marius
Fevang, Børre
Aukrust, Pål
Jørgensen, Silje F.
author_facet Hustad, Nina B.
Degerud, Hanna M.
Hjelmerud, Ingrid
Fraz, Mai S. A.
Nordøy, Ingvild
Trøseid, Marius
Fevang, Børre
Aukrust, Pål
Jørgensen, Silje F.
author_sort Hustad, Nina B.
collection PubMed
description Immunoglobulin replacement therapy with facilitated subcutaneous immunoglobulin (fSCIg) can be self-administrated at home and given at longer intervals compared to subcutaneous immunoglobulin (SCIg) therapy, but real-word experience of home-based fSCIg therapy is limited. Herein we present our real-word clinical experiences with home-based fSCIg therapy using a three-step ramp-up schedule. We registered data from all patients with immunodeficiency starting fSCIg from 01.01.2017 to 31.12.2019. For comparison we also included patients starting conventional SCIg training. Fifty-four patients followed for a median of 18 months (IQR 12, range 0–40), received fSCIg training, and 84 patients received conventional SCIg training. Out of 54 patients starting with fSCIg, 41 patients had previous experience with conventional SCIg therapy, and the main reason for starting fSCIg was ‘longer intervals between therapies’ (n=48). We found an increase in training requirement for fSCIg (3 ± 1 [2-9] days) compared to conventional SCIg (2 ± 0 [1-7] days), P< 0.001 (median ± IQR, [range]). For fSCIg training, IgG levels were stable from baseline (8.9 ± 2.3 g/L), 3-6 months (10.2 ± 2.2 g/L) and 9-12 months (9.9 ± 2.3 g/L), P= 0.11 (mean ± SD). The most common side-effect was: ‘rubor around injection site’ (n=48, 89%). No patients experienced severe adverse events (grade 3-4). Thirteen patients (24%) discontinued fSCIg therapy due to local adverse events (n=9), cognitive/psychological difficulties (n=6) and/or systemic adverse events (n=3). In conclusion, fSCIg training using a three-step ramp-up schedule is safe and well tolerated by the majority of patients, but requires longer training time compared to conventional SCIg.
format Online
Article
Text
id pubmed-8127781
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-81277812021-05-18 Real-World Experiences With Facilitated Subcutaneous Immunoglobulin Substitution in Patients With Hypogammaglobulinemia, Using a Three-Step Ramp-Up Schedule Hustad, Nina B. Degerud, Hanna M. Hjelmerud, Ingrid Fraz, Mai S. A. Nordøy, Ingvild Trøseid, Marius Fevang, Børre Aukrust, Pål Jørgensen, Silje F. Front Immunol Immunology Immunoglobulin replacement therapy with facilitated subcutaneous immunoglobulin (fSCIg) can be self-administrated at home and given at longer intervals compared to subcutaneous immunoglobulin (SCIg) therapy, but real-word experience of home-based fSCIg therapy is limited. Herein we present our real-word clinical experiences with home-based fSCIg therapy using a three-step ramp-up schedule. We registered data from all patients with immunodeficiency starting fSCIg from 01.01.2017 to 31.12.2019. For comparison we also included patients starting conventional SCIg training. Fifty-four patients followed for a median of 18 months (IQR 12, range 0–40), received fSCIg training, and 84 patients received conventional SCIg training. Out of 54 patients starting with fSCIg, 41 patients had previous experience with conventional SCIg therapy, and the main reason for starting fSCIg was ‘longer intervals between therapies’ (n=48). We found an increase in training requirement for fSCIg (3 ± 1 [2-9] days) compared to conventional SCIg (2 ± 0 [1-7] days), P< 0.001 (median ± IQR, [range]). For fSCIg training, IgG levels were stable from baseline (8.9 ± 2.3 g/L), 3-6 months (10.2 ± 2.2 g/L) and 9-12 months (9.9 ± 2.3 g/L), P= 0.11 (mean ± SD). The most common side-effect was: ‘rubor around injection site’ (n=48, 89%). No patients experienced severe adverse events (grade 3-4). Thirteen patients (24%) discontinued fSCIg therapy due to local adverse events (n=9), cognitive/psychological difficulties (n=6) and/or systemic adverse events (n=3). In conclusion, fSCIg training using a three-step ramp-up schedule is safe and well tolerated by the majority of patients, but requires longer training time compared to conventional SCIg. Frontiers Media S.A. 2021-04-27 /pmc/articles/PMC8127781/ /pubmed/34012453 http://dx.doi.org/10.3389/fimmu.2021.670547 Text en Copyright © 2021 Hustad, Degerud, Hjelmerud, Fraz, Nordøy, Trøseid, Fevang, Aukrust and Jørgensen https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Hustad, Nina B.
Degerud, Hanna M.
Hjelmerud, Ingrid
Fraz, Mai S. A.
Nordøy, Ingvild
Trøseid, Marius
Fevang, Børre
Aukrust, Pål
Jørgensen, Silje F.
Real-World Experiences With Facilitated Subcutaneous Immunoglobulin Substitution in Patients With Hypogammaglobulinemia, Using a Three-Step Ramp-Up Schedule
title Real-World Experiences With Facilitated Subcutaneous Immunoglobulin Substitution in Patients With Hypogammaglobulinemia, Using a Three-Step Ramp-Up Schedule
title_full Real-World Experiences With Facilitated Subcutaneous Immunoglobulin Substitution in Patients With Hypogammaglobulinemia, Using a Three-Step Ramp-Up Schedule
title_fullStr Real-World Experiences With Facilitated Subcutaneous Immunoglobulin Substitution in Patients With Hypogammaglobulinemia, Using a Three-Step Ramp-Up Schedule
title_full_unstemmed Real-World Experiences With Facilitated Subcutaneous Immunoglobulin Substitution in Patients With Hypogammaglobulinemia, Using a Three-Step Ramp-Up Schedule
title_short Real-World Experiences With Facilitated Subcutaneous Immunoglobulin Substitution in Patients With Hypogammaglobulinemia, Using a Three-Step Ramp-Up Schedule
title_sort real-world experiences with facilitated subcutaneous immunoglobulin substitution in patients with hypogammaglobulinemia, using a three-step ramp-up schedule
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8127781/
https://www.ncbi.nlm.nih.gov/pubmed/34012453
http://dx.doi.org/10.3389/fimmu.2021.670547
work_keys_str_mv AT hustadninab realworldexperienceswithfacilitatedsubcutaneousimmunoglobulinsubstitutioninpatientswithhypogammaglobulinemiausingathreesteprampupschedule
AT degerudhannam realworldexperienceswithfacilitatedsubcutaneousimmunoglobulinsubstitutioninpatientswithhypogammaglobulinemiausingathreesteprampupschedule
AT hjelmerudingrid realworldexperienceswithfacilitatedsubcutaneousimmunoglobulinsubstitutioninpatientswithhypogammaglobulinemiausingathreesteprampupschedule
AT frazmaisa realworldexperienceswithfacilitatedsubcutaneousimmunoglobulinsubstitutioninpatientswithhypogammaglobulinemiausingathreesteprampupschedule
AT nordøyingvild realworldexperienceswithfacilitatedsubcutaneousimmunoglobulinsubstitutioninpatientswithhypogammaglobulinemiausingathreesteprampupschedule
AT trøseidmarius realworldexperienceswithfacilitatedsubcutaneousimmunoglobulinsubstitutioninpatientswithhypogammaglobulinemiausingathreesteprampupschedule
AT fevangbørre realworldexperienceswithfacilitatedsubcutaneousimmunoglobulinsubstitutioninpatientswithhypogammaglobulinemiausingathreesteprampupschedule
AT aukrustpal realworldexperienceswithfacilitatedsubcutaneousimmunoglobulinsubstitutioninpatientswithhypogammaglobulinemiausingathreesteprampupschedule
AT jørgensensiljef realworldexperienceswithfacilitatedsubcutaneousimmunoglobulinsubstitutioninpatientswithhypogammaglobulinemiausingathreesteprampupschedule